Medullary thyroid carcinoma: Who's on first?

Thyroid

Volumn 22, Issue 5, 2012, Pages 451-453

  Hu, Mimi I ^a   Cote, Gilbert J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANDETANIB;

CANCER GROWTH; CANCER SIZE; CARCINOGENESIS; DIAGNOSTIC VALUE; EDITORIAL; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; NEUROFIBROMATOSIS; ONCOGENE RET; PARATHYROID HYPERPLASIA; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTO ONCOGENE; SOMATIC MUTATION; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TREATMENT RESPONSE;

FEMALE; HUMANS; MALE; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 84860491640     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.2205.ed     Document Type: Editorial

References (29)

1. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856.
2. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460.
3. Rohmer V, Vidal-Trecan G, Bourdelot A, Niccoli P, Murat A, Wemeau JL, Borson-Chazot F, Schvartz C, Tabarin A, Chabre O, Chabrier G, Caron P, Rodien P, Schlumberger M, Baudin E 2011 Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines. J Clin Endocrinol Metab 96:E509-518.
4. Elisei R, Romei C, Renzini G, Bottici V, Cosci B, Molinaro E, Agate L, Cappagli V, Miccoli P, Berti P, Faviana P, Ugolini C, Basolo F, Vitti P, Pinchera A 2012 The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. J Clin Endocrinol Metab 97:426-435.
5. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ 2012 Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30:134-141.
6. Weinstein IB, Joe A 2008 Oncogene addiction. Cancer Res 68:3077-3080; discussion 3080.
7. Jackson CE, Block MA, Greenawald KA, Tashjian AH Jr 1979 The two-mutational-event theory in medullary thyroid cancer. Am J Hum Genet 31:704-710.
8. Simpson NE, Kidd KK, Goodfellow PJ, McDermid H, Myers S, Kidd JR, Jackson CE, Duncan AM, Farrer LA, Brasch K, Castiglione C, Genel M,Gertner J, Greenberg CR, Gusella JF, Holden JJA, White BN 1987 Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 328:528-530.
9. Nelkin BD, de Bustros AC, Mabry M, Baylin SB 1989 The molecular biology of medullary thyroid carcinoma. A model for cancer development and progression. JAMA 261:3130-3135.
10. Nelkin BD, Nakamura Y, White RW, de Bustros AC, Herman J, Wells SA Jr, Baylin SB 1989 Low incidence of loss of chromosome 10 in sporadic and hereditary human medullary thyroid carcinoma. Cancer Res 49:4114-4119.
11. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B 1997 Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73.
12. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580.
13. Takahashi M, Cooper GM 1987 RET transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol 7:1378-1385.
14. Takahashi M, Ritz J, Cooper GM 1985 Activation of a novel human transforming gene, RET, by DNA rearrangement. Cell 42:581-588.
15. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G 1990 PTC is a novel rearranged form of the RET protooncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557-563.
16. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP 1995 Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381-383.
17. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G, Lips CJM, Buys CHCM 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375-376.
18. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR, Futreal PA 2011 COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39:D945-950.
19. Sanger Institute. COSMIC Catalogue Of Somatic Mutations In Cancer. www.sanger.ac.uk/genetics/CGP/cosmic (accessed February 2, 2012).
20. Morandi A, Plaza-Menacho I, Isacke CM 2011 RET in breast cancer: functional and therapeutic implications. Trends Mol Med 17:149-157.
21. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, Kim YT, Kim JI, Kang JH, Seo JS 2012 A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from wholegenome and transcriptome sequencing. Genome Res 22: 436-445.
22. Dawson DM, Lawrence EG, MacLennan GT, Amini SB, Kung HJ, Robinson D, Resnick MI, Kursh ED, Pretlow TP, Pretlow TG 1998 Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer. J Natl Cancer Inst 90:519-523.
23. Zeng Q, Cheng Y, Zhu Q, Yu Z, Wu X, Huang K, Zhou M, Han S, Zhang Q 2008 The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer. J Int Med Res 36:656-664.
24. Romei C, Ugolini C, Cosci B, Torregrossa L, Vivaldi A, Ciampi R, Tacito A, Basolo F, Materazzi G, Miccoli P, Vitti P, Pinchera A, Elisei R 2012 Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid 22:476-481.
25. Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Thomas GA, Ponder BA 1996 Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 56:2167-2170.
26. Schilling T, Burck J, Sinn HP, Clemens A, Otto HF, Hoppner W, Herfarth C, Ziegler R, Schwab M, Raue F 2001 Prognostic value of codon 918 (ATG/ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 95:62-66.
27. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A 2008 Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682-687.
28. Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, Salama S, Al- Muhayawi S, Chaudhary A, Hamour O, Abuzenadah A, Gari M, Al-Qahtani M 2011 Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Anticancer Res 31:4179-4183.
29. Moura MM, Cavaco BM, Pinto AE, Leite V 2011 High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 96:E863-868.